Project Grant R21AI190892
Award Date
3/21/25
Completion Date
2/28/27
Dollars Obligated
$228K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
The Project Grant award R21AI185735 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a broad-spectrum influenza vaccine. The $230,000 award to the Scripps Research Institute will fund efforts to evaluate recently discovered neuraminidase (NA) broadly neutralizing antibodies (bNAbs) for their potential in a "germline targeting" vaccine design strategy. This...
The federal Project Grant award R01AI184867, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate how innate immune signals regulate the development of effective B cell responses during influenza infection. The $596,636 award, with a project period from June 2024 to May 2029, aims to determine the role of B cell-intrinsic Toll-like receptor (TLR) signaling pathways...
This Cooperative Agreement award in the amount of $1,352,292 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a research project to develop a high-resolution profile of influenza virus and human immune system dynamics during natural infection. The research aims to: (1) identify reliable immune correlates of reduced viral shedding and transmission risk, and (2) define...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $356,396 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to William Marsh Rice University. The grant, titled "Improving Vaccination Through Biomimicry: Recapitulating the Antigen Kinetics of Native Infections Using a Modular Vaccine Delivery System," aims to develop vaccine formulations that exhibit exponential antigen release to mimic the kinetics of native infections,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,246,617 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the La Jolla Institute for Immunology. The project aims to capture existing and generate new experimental data to connect immunological variables with influenza vaccine breadth and durability. The awardee will develop computational models to predict vaccine outcomes and host an annual public prediction contest...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $355,813 to the University of Melbourne to conduct research on influenza vaccines for older adults. The project aims to assess the combination and longitudinal effects of repeated administration of standard versus enhanced influenza vaccines on antibody and cellular immune responses in this population. Key...
The University of Chicago has been awarded a $1,225,986 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 5-year project is to develop computational models that can describe the conditions leading to strong, durable, and broadly protective adaptive immune responses to influenza vaccination, especially in individuals with prior influenza virus exposure. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,528 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University to conduct research into sex differences in vaccine-induced immunity. The project aims to investigate the potential role of mTOR activation and metabolic signaling in B cells as a mechanism governing sex-specific differences in humoral immune responses following influenza vaccination. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $565,200 Cooperative Agreement to the University of California, Irvine (UC Irvine) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports a 5-year research project to investigate the impact of aging on human B cell vaccine responses.
The key products and services to be delivered under this award include:
Identifying age-related B cells (ABCs) in peripheral blood and lymphoid...
This federal Project Grant award, valued at $502,075.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection. The research will compare the protection provided by intranasal mucosal adjuvanted vaccination versus intramuscular parenteral...